Contrary to expectations based on in vitro experiments, we previously found that pancreatic IL-10 did not inhibit autoimmune diabetes but accelerated it in an MHC-dependent manner. Therefore, the ability of IL-10 to overcome the absence of all non-MHC diabetes susceptibility (Idd) alleles was studied in transgenic mice expressing pancreatic IL-10 backcrossed to BIO.H2e7 congenic mice, which have no Idd alleles other than NOD MHC (1-12"7). IL-10 transgenic backcross 1 (BC1) mice with H2gT/e 7 haplotype devdoped dear-cut insulitis and diabetes, but neither transgenic mice with the H2g/b haplotype nor nontransgenic BC1 mice did so. Further implicating IL-10 in autoimmune diabetes, anti-IL-10 antibody treatment inhibited the development of insulifis in NOD mice. These results suggest that IL-10 may be necessary and sufficient for producing autoimmune diabetes in conjunction with NOD MHC homozygosity and that some Idd genes may be related to the regulation of IL-10.
I
'L-10 is produced mainly by Th2 cells, macrophages, and .Lyl + B lymphocytes (1, 2) . IL-10 inhibits Thl cell proliferation and cytokine production in the presence of macrophages by blocking costimulatory activity in vitro (3, 4) . These results suggest that IL-10 is a potential agent for the treatment of autoimmune diseases or allograft rejection in vivo. However, experiments using transgenic mice expressing IL-10 in pancreatic 13-(Ins-IL-10 mice) or a-cells and their offspring from backcrosses to NOD mice demonstrated that pancreatic IL-10 did not inhibit but, instead, accelerated autoimmune diabetes in an MHC-dependent manner (5-7). Furthermore, results from the backcross experiment suggested that pancreatic IL-10 might overcome the absence of NOD homozygosity at a substantial number of non-MHC diabetes-susceptibility (Idd) loci (6) . The experiments described in this report were undertaken to determine whether pancreatic IL-10 is able to replace all known non-MHC Idd alleles in NOD mice and whether IL-10 is sufficient for the development ofautoimmune diabetes in the transgenic mouse model when an appropriate MHC is provided. In addition, the role of IL-10 in the pathogenesis of natural autoimmune diabetes in NOD mice was studied.
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Materials and Methods
Animals. Ins-IL-10 mice of the C57BL/6 background were derived by repeated backcrossing oflns-IL-10 mice (8) to C57BL/6 mice (B6.Ins-IL-10 mice). Neither insulitis nor diabetes was observed in B6.Ins-IL-10 mice or the original Ins-IL-10 mice of BALB/c background (8) . After four backcross generations, these mice were subsequently bred with B10.H2g 7 congenic mice that have NOD MHC (H2g 7) but no other NOD-derived Idd alleles (9) . IL-10-transgenic F1 mice were backcrossed to B10.H2 g7 twice to derive IL-10-positive backcross 1 (BC1) mice that were homozygous for the NOD MHC but without other NODderived Idd alleles: BC1 [FI(B6.Ins-IL-10 X B10.H2eT) X B10. H2g 7] ( Fig. 1) . In another set of breedings, IL-10-transgenic F1 mice were bred with NOD mice to derive F1 X NOD mice: [FI( B6.Ins-IL-10 X B10.H2eT) X NOD]. F1 X NOD mice were heterozygous at all non-MHC Idd loci (Fig. 1 ).
The incidence of diabetes was determined by weekly measurement of blood glucose starting at 5 wk and lasting up to 3 mo of age. Diabetes was defined as a single non fasting blood glucose level over 300 mg/dl or two consecutive measurements over 230 mg/dl in ocular blood samples tested with a Glucometer 3 (Miles Inc., Elkhart, IN).
MHC typing was done by PCR amplification of the I-A~ chain (primers, CTCTTCAGGCTGGGATGCTCCACAT and TGTCTTTTCTGTCACCCTAGAACAG) followed by Mspl digestion. The amplified material from homozygous (H2g7/g 7) mice was not cut with Mspl, yielding a single fragment of 282 bp. That from heterozygous (H2g 7/b) mice contained 282-, 149-, and 133-bp fragments.
mAb Treatment. mAbs were produced by making ascites in P32-labeled riboprobes were prepared by in vitro transcription of linearized expression vectors harboring bacteriophage promoters. The riboprobes were hybridized to 5 bLg of each R.NA sample and control ttLNA. The protected R N A hybrid and the respective probes were analyzed on a 8% polyacrylamide gel. The signal was quantified using x-ray densitometry and standardized against the band intensity of a control probe (GAPDH).
Immunohistochemistry. Acetone-fixed fresh frozen sections were incubated with anti-B220 (PharMingen, San Diego, CA), anti-CD4 (PharMingen), anti-CD8 (PharMingen) or anti-Mac-1 (Boehringer Mannheim, Indianapolis, IN) Ab. Incubation with an appropriate biotinylated secondary Ab (Vector Laboratories, Burlingame, CA), and then with avidin-biotin-peroxidase complex (Vector Laboratories) followed. After color reaction with diaminobenzidine (Sigma), the sections were counterstained with methyl green. Figure 1 . Ins-lL-10 mice of the C57BL/6 background (B6.Ins-IL-10) were derived by repeated backcrossing to C57BL/6 mice. They were bred with B10.H2 r mice, and transgenic F1 mice were backcrossed to B10.H2 g7 mice to derive transgenic mice that were homozygous for the NOD MHC (H2 ~7/g7) but had no other NOD-derived Idd alleles (BC1). Tramgenic F1 mice were also bred with NOD mice to derive mice homozygnus for the NOD MHC but heterozygous at all non-MHC Idd loci (F1 • NOD). The immunogenic significance of the F1 • NOD breeding experiment is similar to that of the B10.H2 .7 backcross experiment, because all ldd alleles of NOD defined in previous backcross studies were either recessive or dominant with very low penetrance. SCID mice or nude mice with injections of 5 • 106 SXC-1 or JES5-2A5.11 hybridoma cells given 1 wk after pristane (Sigma Chemical Co., St. Louis, MO) injection. Protein was purified from the ascites by using 2-step ammonium sulfate precipitation, and Ig level was quantified with a Bradford protein assay. Anti-IL-10 mAb of the rat IglVl (1 ~g/injection) or rat IgG class (0.5 p~g/injection) was administered to the experimental group three times a week. Control mice were treated with either PBS or rat IgG (Sigma). Scoring ofinsulitis was done by examining 2 H&E-stained slides taken from different sites of one pancreatic block. If the number of islets was below 10 in both samples, one more slide was prepared from a different site. The degree of insulitis was classified into three categories: no insulitis, periinsulitis with or without minimal lymphocytic infiltration into the islets, and insulitis.
The Chi-square test was employed for statistical analysis. RNase Protection Assay. Splenic P, NA was isolated 4 h after i.p. injection of 350 p~g LPS (Sigma) by mechanical homogenization in guanidium thiocyanate solution and acid-phenol extraction.
Results and Discussion
Before 3 mo of age, 8 of 19 IL-10-positive H297/r 7 BC1 mice (42%) became diabetic ( Table 1) . If fact, most of them developed diabetes before 2 mo of age, with no apparent difference in incidence according to sex. In contrast, neither transgenic BC1 mice with H2g v/b haplotype (n = 14) nor nontransgenic BC1 mice (H2g 7/g7, n = 16; H2g 7/b, n = 17) ever developed diabetes during this period. Histopathological examination revealed clearcut insulitis in the pancreata of IL-10-transgenic mice with the H2g7/g 7 haplotype, regardless o f the presence of diabetes (61% o f the total islets examined at the time of diabetes onset or at 3 mo of age) ( (Fig. 2 C) , and occasional islets showed minimal lymphocytic infiltration but without islet destruction. Pancreatic islets of nontransgenic mice of both M H C haplotypes were free from periinsulitis or insulitis. To determine whether autoimmunity accounted for the diabetes and insulitis observed here, we transplanted neonatal B10.H2 g7 pancreata into diabetic or nondiabetic male IL-10-transgenic BC1 mice of the H 2 g7/g7 haplotype. As a result, massive lymphocytic infiltration with abortive islet formation was observed in all pancreatic grafts 3-4 wk after transplantation (n = 3) (Fig. 2 E) , whereas control grafts placed into the nontransgenic BC1 mice of the H 2 g7/,e7 haplotype formed mature islets, with only very rare inflammatory cells (n = 3) (Fig. 2 D) . The results from the graft experiment and strict dependence of diabetes on N O D M H C homozygosity indicate that autoimmunity was indeed respon- (Fig. 2 F) . That the incidence of diabetes was less than 100% in both B10.H2 .7 BC 1 and F1 X N O D mice might be attributed to the fact that only 10% of total islet cell mass would be sufficient for glucose homeostasis and that the observation period was relatively short. Some environmental factor(s) might also be involved, resulting in diabetes in some but not all mice, similar to the N O D parental strain. In contrast to these results, systemic IL-10 administration reportedly decreased the incidence of diabetes in N O D mice (10) . This discrepancy might be caused by the different site of cytokine administration (systemic vs. local), which was most clearly demonstrated in case o f TGF-I31 (11) . Additionally, the time point of IL-10 administration was 10 wk of age in the study involving systemic administration (10), which is much later than that experienced by Ins-IL-10 mice (8) .
The mechanism of IL-10-induced autoimmunity is not clearly understood. Transgenic production o f IL-10 leads to induction of adhesion molecules and periislet inflammation (8) . However, effects attributable to nonspecific inflammation or increased chemotaxis alone cannot account for the IL-10-mediated induction or acceleration o f autoimmune diabetes observed in our mice. sulting in diversification o f T cell responses through B lymphocytes functioning as APC as suggested in SLE (19, 20) . Increased M H C class II expression on B lymphocytes by IL-10 might be related to the enhanced antigen presentation by B lymphocytes (21) . Consistent with this, B lymphocytes stained with anti-B220 antibody were the predominant cells infiltrating the pancreata oftransgenic H2 gT/g7 BC1 and F1 • N O D mice as revealed by immunohistochemistry (Fig. 3 A) . CD4 + T lymphocytes were the next most abundant cells (Fig. 3 B) , followed by Mac-1 + macrophages and a small number of CD8 + T lymphocytes (data not shown).
The foregoing outcomes with our transgenic mice did not indicate a role for IL-10 in the development of natural autoimmune diabetes in N O D mice. To address this issue and to learn if IL-10 is necessary for natural autoimmune diabetes, we administered anti-IL-10 Ab to N O D mice and compared the severity of insulitis between treated groups and control groups. In female N O D mice treated for 6 wk starting at 3-4 wk of age (n = 12), the proportion of islets showing insulitis was significantly lower than in control N O D mice treated with PBS or rat IgG (n = 10) (P <0.001) ( Table 2 A) . In another experiment, anti-IL-10 was administered for 3 mo starting when the mice were 3 wk old. Again, virtually no insulitis was observed in their pancreata, whereas insulitis was pronounced in control mice (Table 2  B) . This result concurs with the ability of anti-IL-10 to delay the onset of autoimmunity in N Z B / W (22) and indicates a larger role for IL-10 in a broad spectrum o f autoimmune disorders. These effects might be related to the change in TNF-0~ level by anti-IL-10 as was suggested in the study involving N Z B / W mice; however, regardless of the presence o f secondary mediators o f IL-10, the results suggest an important role for IL-10 in the pathogenesis of autoimmunity. Yet, our results contrast with a report showing no change in the incidence of diabetes by anti-IL-10 administration to N O D mice (10) . However, the N O D mice in that experiment were 10 wk old, a time when effector T lymphocytes are already sensitized to a variety of islet antigens (23, 24) . If IL-10 is involved in the pathogenesis of autoimmune diabetes, the critical point would be the initial sensitization phase by APC, not the effector phase mediated by T lymphocytes. If this hypothesis is correct, abrogation of IL-10 after establishment of autoimmunity might not affect the clinical course of diabetes.
The above results suggest that IL-10 may be necessary and sufficient for the development of autoimmune diabetes in conjunction with N O D M H C homozygosity, and also that some uncharacterized n o n -M H C Idd alleles of N O D mice may be related to abnormal production of IL-10 or abnormal sensitivity to IL-10. To examine whether IL-10 regulation differs in N O D and diabetes-resistant mice, IL-10 m R N A levels in their spleens were quantified after LPS administration by using RNase protection assays. Our preliminary results indicated that the ratio of the IL-10 signal to the control (GAPDH) signal was higher in a 5-mo-old female N O D mouse (124%) and a 7-wk-old female N O D mouse (97%) compared to that in a 7-wk-old female BALB/c (23%) and in a 7-wk-old female C57BL/6 mouse (21%). O n the other hand, the TNF-0t signal normalized for the control signal was highest in the BALB/c mouse (74%), intermediate in the C57BL/6 mouse (47%), and lowest in the 5-mo-old and 7-wk-old N O D mice (both 26%). This preliminary result in mice is consistent with increased IL-10 production in humans with SLE, rheumatoid arthritis or Sjogren's syndrome, suggesting a role for IL-10 regulation not only in autoimmune diabetes but in a broad spectrum of autoimmune diseases (25) . The inverse relationship between IL-10 and TNF-ix signals might relate to the inhibition of TNF-0t expression by IL-10 (22, 26). Moreover, a relationship has been proposed between low TNF-o~ pro- *Effect of anti-IL~10 treatment for 6 wk on insulitis in NOD mice starting at 3-4 wk of age. IL-10 mAb was administered to the experimental group (n = 12), while control mice (n = 10) were treated with either PBS or rat lgG.
The experimental group had a significantly lower proportion of insulitis and periinsulitis. *Effect of anti-IL-10 treatment for 3 mo starting at 3 wk of age. Anti-IL-10 was given to female NOD mice (n = 5), while rat lgG or PBS was given to control mice (n = 8). Again, anti-IL-]0 treatment inhibited the development of insulitis almost completely.
duction itself and the development of autoimmune diseases (27, 28) . The susceptibility to autoimmunity in mice with low TNF-et production could be a consequence of their high IL-10 production. Together, these results strongly suggest a role for IL-10 in the pathogenesis of autoimmune diabetes in both transgenic mice and NOD mice. Previous experiments demonstrating the inhibitory activity of IL-10 were performed in vitro using defined subsets of cells. Immune responses in vivo involve several APC such as dendritic cells, macrophages and B lymphocytes, and their interactions with CD4 § and CD8 § T lymphocytes in which many signals are delivered from one cell to another. Thus, in vivo effects of IL-10 may be different from in vitro findings. B lymphocytes differ from other APCs in that they can concentrate specific proteins with their surface Ig and present even nondominant determinants to T lymphocytes, leading to diversification of T cell responses probably after initial T cell priming to immunodominant determinants by dendritic cells (29) . Previous work has demonstrated the existence of low-affinity autoreactive T lymphocytes escaping from thymic censorship (30, 31) . Thus, we are tempted to speculate that B lymphocytes stimulated by IL-10 in NOD mice would activate those T lymphocytes reactive to a variety of subdominant or cryptic determinants of self antigens, resulting in diversified T cell responses. A role for B lymphocytes in the development of autoimmune diabetes in NOD mice was suggested in an experiment showing abrogation of diabetes by anti-IgM administration (32) . This scenario fits well with the intermolecular and intramolecular spreading of antigenic determinants in autoimmune diabetes and experimental allergic encephalomyelitis (23, 24, 33) . Accordingly, we propose that IL:10 can affect interactions between B and T lymphocytes and the resultant diversification of T cell responses, which are critical to the progression to clinical autoimmune diseases.
